Despite the high prevalence of obesity and overweight in a cohort of patients with prolactinoma, six months of DA treatment and normal PRL levels did not lead to a significant difference in BMI (46). This evidence concerns the gene PRL and obesity due to melanocortin 4 receptor deficiency.